Amarin Corp Plc (AMRN)

[jessellivermore]

iwfal...

Your posts tell me you don't know a lot about EPA, the scientific or clinical literature. This gap in knowledge is clear when you make comments suggesting there likely will be enough adverse events to counter any meager benefit the drug will show...This tells me and everybody on the board that does know a lot the subject, that you are just spouting wind..

Why don't you expand on the bothersome side effects?

There is ample information, direct and indirect, that EPA does and will lower CVD risk...JELIS is something you need a couple of weeks worth of study and reflections on...Maybe you should familiarize yourself with some of the population studies and read Dr. Bernard Sears and learn about eicosanoids .

I do not think there is any chance the RRR in the PE is in doubt...JELIS curves which track the secondary prevention cohort which is very close to R-I show that the RRRs do not increase to any meaningful degree after a couple of years. This means if the PE RRR was very weak at the 60% interim it is very unlikely its going to get stronger over time. And continuing the trial is not likely to resurrect a dead PE. Actually it makes more sense to continue the trial if the PE RRR is very strong...because there is a greater likelihood of having some of the smaller subsets (the additional datapoints) to show strong significance...If the PE is marginal or disappointing there is very little chance, as you imagine, that any of the lesser data points are going to be a big surprise..The reason to continue the trial is not to raise the RRR...The reason to continue is to get more events.

":>) JL